EDWARD DEMPSEY, MD
Osteopathic Medicine at 16 Ave, Denver, CO
License number
Colorado 28083
Category
Osteopathic Medicine
Type
Hypertension Specialist
License number
Colorado 28083
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000
(303) 493-7000
Personal information
See more information about EDWARD DEMPSEY at radaris.comName
Address
Phone
7221 S Sheridan Ct, Littleton, CO 80128
6018 Blue Ridge Dr APT A, Highlands Ranch, CO 80130
538 Ulster Way, Denver, CO 80230
6606 S Chase Ct, Littleton, CO 80123
10492 W Ida Pl, Littleton, CO 80127
Organization information
See more information about EDWARD DEMPSEY at bizstanding.comEdward Dempsey MD
1055 Clermont St, Denver, CO 80220
Industry:
Internist
Phone:
(303) 393-2869 (Phone)
Edward Charles Dempsey
Professional information
See more information about EDWARD DEMPSEY at trustoria.com
Dr. Edward C Dempsey, Aurora CO - MD (Doctor of Medicine)
Dr. Edward C Dempsey, Aurora CO - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
12605 E 16Th Ave, Aurora 80045
(720) 848-5300 (Phone)
(720) 848-5300 (Phone)
Certifications:
Critical Care Medicine, 1989, Internal Medicine, 1986, Pulmonary Disease, 1988
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
12605 E 16Th Ave, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
Education:
Medical School
Harvard Medical School
Graduated: 1982
Yale-New Haven Medical Center Program
University Of Colorado (University Hospital) Program
Harvard Medical School
Graduated: 1982
Yale-New Haven Medical Center Program
University Of Colorado (University Hospital) Program
Edward C Dempsey, Aurora CO
Edward C Dempsey, Aurora CO
Specialties:
Pulmonologist
Address:
12605 E 16Th Ave, Aurora, CO 80045
12700 E 19Th Ave, Aurora, CO 80045
12700 E 19Th Ave, Aurora, CO 80045
Education:
Harvard Medical School - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Pulmonary Disease and Critical Care Medicine (Internal Medicine)
Yale New Haven Psychiatric Hospital - Residency - Internal Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Pulmonary Disease and Critical Care Medicine (Internal Medicine)
Yale New Haven Psychiatric Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)
Treatment Of Pulmonary Vascular Remodeling With Neprilysin
Treatment Of Pulmonary Vascular Remodeling With Neprilysin
US Patent:
2012012, May 17, 2012
Filed:
Sep 1, 2011
Appl. No.:
13/224126
Inventors:
Edward C. Dempsey - Aurora CO, US
International Classification:
A61K 38/48, A61P 11/00, A61P 9/00, A61P 9/12, G01N 33/573, C12Q 1/68, C12Q 1/37, A61K 48/00, A61P 29/00
US Classification:
424 9467, 514 44 R, 435 74, 435 613, 435 612, 435 23, 435 618
Abstract:
The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.
Method Of Using Pkc Inhibiting Compounds To Treat Vascular Disease
Method Of Using Pkc Inhibiting Compounds To Treat Vascular Disease
US Patent:
6228843, May 8, 2001
Filed:
Apr 21, 2000
Appl. No.:
9/557038
Inventors:
Edward C. Dempsey - Denver CO
Assignee:
University Technology Corporation - Boulder CO
International Classification:
A01N 4304
US Classification:
514 31
Abstract:
A method for treating pulmonary and systemic vascular diseases associated with cardiac hypotrophy, dysfunction or failure that involves the administration of an effective amount of a PKC antagonist to a patient suffering from one of such diseases is disclosed. PKC antagonists are selected from bryostatin derivatives and more preferably from bryostatin-1. The disease states treatable in accordance with the present invention are characterized by alterations in vascular structure, vascular tone, myocardial hypotrophy, dysfunction or failure, idiopathic pulmonary hypertension and chronic hypoxic pulmonary hypertension. Particular formulations include bryostatin-1 in an effective amount to treat one or more of the above-referenced diseases.